Versant Capital Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
Versant Capital Management's PTCT Position: Q3 2026 in Review
Versant Capital Management reduced its PTC Therapeutics (PTCT) stake by 32% in Q3 2026, selling an estimated $655 and leaving 19 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.
Versant Capital Management first reported a position in PTCT in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.28K in Q2 2026. 359 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.
- Versant Capital Management held 19 shares of PTC Therapeutics worth $1.23K as of Q3 2026.
- Versant Capital Management sold 9 PTC Therapeutics shares in Q3 2026, an estimated $655.
- PTC Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2683 holding.
- Versant Capital Management first reported a position in PTC Therapeutics in Q2 2021 and has held it in 8 quarters since.
- Versant Capital Management's PTC Therapeutics position peaked at $2.28K in Q2 2026.
- 359 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.